For Immediate Release

Resverlogix’s HDL Preclinical Data is Published in Current Opinion in Investigational Drugs

Calgary, AB, September 12, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that a portion of the Company’s key preclinical data has been published in Current Opinion in Investigational Drugs. The article titled “Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis” is an article that details the many approaches to increasing ApoA-I/HDL.

Mr. Donald McCaffrey, President & CEO of Resverlogix stated, “We are pleased to have our data included in this important journal. The data contained in this publication is an exciting segment of the comprehensive data set that Resverlogix will submit to the US Food and Drug Agency (FDA) as part of the Company’s Investigational New Drug (IND) application. A Phase I Clinical trial is expected to start as early as the fourth quarter of 2007.”

About ApoA-I/HDL
ApoA-I is the key protein in high-density lipoprotein (HDL or the “good cholesterol”). Over the past 50 years clinical studies have clearly demonstrated the beneficial role of ApoA-I by showing both the reversal of arterial plaque and reduction of CVD risk. Thereby ApoA-I has secured the moniker, the cardioprotective protein.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets significant unmet needs. The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com